Therapeutic Drugs for Central Nervous System (CNS) Disorders: Technologies and Global Markets

December 02, 2010

Wellesley, Mass. – According to a new technical market research report, THERAPEUTIC DRUGS FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS:TECHNOLOGIES AND GLOBAL MARKETS (PHM068A) from BCC Research (www.bccresearch.com), the global market value for therapeutic drugs for CNS disorders is an estimated $79 billion in 2010, but is expected to increase to nearly $82 billion in 2015, for a 5-year compound annual growth rate (CAGR) of 0.7%.

The largest segment of the market, psychiatry, is expected to decrease at a 5-year CAGR of -12.1%, from $20.5 billion in 2010 to $10.8 billion in 2015.

The second-largest segment, depression, is expected to decrease to a value of $9.7 billion in 2015 from $15.8 billion in 2010. Thus, the 5-year CAGR is projected to be -9.4%.

The multiple sclerosis/Parkinson’s disease segment of the market will increase only slightly over the next 5 years, from an estimated $13.2 billion in 2010 to $13.9 billion in 2015, for a CAGR of 1%.

The epilepsy/convulsion segment will rise at a CAGR of 5.9%, increasing from $8.4 billion in 2010 to $11.2 billion in 2015.

Other segments include Alzheimer’s disease, ADHD/narcolepsy, migraine, and other CNS disorders, which include hypnotic/sedatives segment, sleep, diet and other associated diseases that use treatments such as Botox.

This study provides a comprehensive analysis of central nervous system therapies on a global basis. Its aim is to provide a range of information, from detailed product analyses within disease subsegments to overall industry trends, in order to quantify and qualify the market for therapeutic drug products in the central nervous system sector. Individual products are forecast on a global basis, as are overall segments.

Market growth has been spurred by the introduction of differentiated therapies due to novel mechanism of action, such as serotonin and norepinephrine reuptake inhibitors (SNRIs). In contrast to technical innovation, patent expiry is producing a headwind that will cause the overall market to remain essentially flat through the forecast period.

This report is an invaluable tool for business planners, acquisition specialists, licensing strategists, product managers, investors, investor consultants and anyone interested in the central nervous system market, its products, its industry participants and its future.

Therapeutic Drugs for Central Nervous System (CNS) Disorders: Technologies and Global Markets( PHM068A )
Publish Date: Sep 2010    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.